Synagis palivizumab 50mg/0.5 mL Single-Dose Vial

Synagis palivizumab 50mg/0.5 mL Single-Dose Vial is a highly effective medication used for the prevention of serious respiratory tract infections caused by the respiratory syncytial virus (RSV) in infants and children. RSV is a common virus that can lead to severe respiratory infections in young children, particularly those with weakened immune systems. Synagis palivizumab, with its active ingredient 50mg of palivizumab, is administered by injection and works by boosting the child's immunity to fight against RSV. This medication has been proven to reduce the severity and incidence of RSV infections in children, making it an essential tool in pediatric health care. Furthermore, Synagis palivizumab 50mg has been shown to significantly reduce hospitalizations and the need for intensive care in children who are at high risk of contracting RSV. With its ease of administration and minimal side effects, this medication is a crucial component in preventing serious respiratory complications in young children, making it a highly sought-after and beneficial treatment option.

Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.

Indications:

• Synagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:
• with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
• with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
• with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season